The annual Early Detection of Cancer Conference is organised by Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford to bring together experts in early detection from multiple disciplines to share ground-breaking research and progress in the field.
This year, our largest contingent of Oxford early detection researchers travelled to London to participate. The conference included sessions on
- Inequalities in cancer detection and diagnosis
- Understanding pre-cancers to enable detection
- Risk stratification to inform early detection
- Multicancer early detection – beyond ctDNA
Featuring OxCODE research
Seven OxCODE researchers presented at the meeting:
- Associate Professor Brian Nicholson (Nuffield Department of Primary Care Health Sciences) gave a talk on “Progress and priorities for risk stratification (with tests) in Primary Care”
- Dr George Atkinson (Mathematical Institute) presented a poster entitled “Integrating digital pathology, mathematical modeling, and spatial analysis for enhanced detection and risk assessment”
- Dr James Chettle (Blagden group, Department of Oncology) presented a poster entitled “The RNA binding protein LARP1 drives tumorigenesis and can be exploited for the early detection of breast and ovarian cancer”
- Miriam Dixon-Zegeye (Blagden group, Department of Oncology) presented a poster entitled “Trial in progress: cancer precision prevention trial of metformin in adults with Li Fraumeni Syndrome (MILI): embedding translational biology into clinical trials”
- Masato Inoue (Song group, Ludwig Institute for Cancer Research) presented a poster entitled “A human tissue atlas of DNA methylation and hydroxymethylation”
- Dr Eoghan Mulholland (Leedham group, Wellcome Centre for Human Genetics) presented a poster entitled “Epithelial Grem1 drives ectopic stem cell niche formation through stromal remodelling and tissue co-evolution in intestinal dysplasia initiation”
- Dr Dimitris Vavoulis (Schuh group, Department of Oncology) presented a poster entitled Multimodal cell-free DNA whole-genome analysis combined with TAPS reveals cancer signals in patients presenting with symptoms”
The next conference is planned as an in-person event in San Francisco in October 2024.